BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR).
Bugworks is developing a novel class of antibiotics to tackle the problem of Antimicrobial Resistance (AMR).
Bugworks was founded in 2014, the company is headquartered in Bangalore, India, with offices in US and Australia.
Bugworks has unlocked a strategy ELUDE™, to evade eﬄux pumps. ELUDE™ continues to provide multiple leads that are potent against Gram negative and Gram positive bacteria.
Bugworks is backed by University of Tokyo Edge Capital (UTEC), Global Brain Corporation (Global Brain) Japan, Acquipharma Holdings and others. The company raised $7.5M in a new round of funding on Apr 22, 2020. This brings Bugworks' total funding to $16.5M to date.